PCN65 HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH STAGE III OR IV FOLLICULAR LYMPHOMA RECEIVING 90Y-IBRITUMOMABTIUXETAN FOLLOWING FIRST-LINE CHEMOTHERAPY
Abstract
Authors
K Gondek A Valderrama A Rohatiner A Bischof-Delaloye J Radford F Morschhauser A Van Hoof B Putz M Kunz A Hagenbeek